Life with protective measures for COVID-19 has become increasingly normal for most of the world. Governments have implemented mandatory masks in public places, social distancing, and other precautionary measures, but continue to explore more accurate ways to apply these measures.

A huge area of interest for governments and researchers alike is “immunity passports.” The idea is that someone who has already recovered from COVID-19 develops antibodies to the virus that will remain in their body for at least a few months. This means they are much less likely to be re-infected and develop symptoms from the virus, making them safer candidates for travel and work.

However, the use of immunity passports has been hampered partly by inaccurate testing. A false-positive antibody test in a person who is not immune may lead that individual to believe that they are immune and engage in high-risk activities that may lead to a true infection.

 A false negative antibody test may cause an individual, who is already immune, to be unnecessarily re-screened for the virus for travel or work-related purposes.

The inaccuracy of these antibody tests is partly due to the viral proteins used in these assays. Most tests in the market use only one or a limited number of proteins from COVID-19.

Scientists at Qatar Foundation’s Sidra Medicine are working on developing a more effective antibody test that looks at multiple types of antibodies against the different protein components of the COVID-19 virus, as well as against the other common human coronaviruses.

Since the test is also high-throughput and has been developed locally, it is more affordable than all commercially available tests. The antibody tests run by Sidra Medicine indicate that it provides more detailed information about each person’s immune response.

Dr. Patrick Tang, Division Chief of Pathology Sciences at Sidra Medicine

Moreover, Dr. Jean Charles Grivel, Director at the Deep Phenotyping Core at Sidra Medicine, stated that their current work in collaboration with other entities will assess the reactivity against all seven human coronaviruses.

“We are working with other entities in Qatar to figure out if antibodies to other coronaviruses impact immunity and how it affects the clinical trajectory of infected patients,” he added.

According to Dr. Patrick Tang, Division Chief of Pathology Sciences at Sidra Medicine, if this test can be applied to a larger population, it would definitely improve the accuracy of the results. He says, “Commercially available serology tests have an accuracy rate of about 85 to 90 percent. If we had a more accurate serology test, we have a greater degree of assurance about who is immune and not likely to become symptomatic if exposed to the virus again. This would mean that these people would be safe for customer-facing duties, or to travel or participate in public gatherings and group activities.”

---

Make sure to check out our social media to keep track of the latest content.

Instagram - @qatarliving

Twitter - @qatarliving

Facebook - Qatar Living

YouTube - qatarlivingofficial